PYK2


  • PF-562271 EY0368

    PF-562271, which is a potent ATP-competitive Pyk2/FAK dual inhibitor, has completed phase I clinical trial and is considered to be a promising drug for patients with solid tumors. PF-562271是一种有效的,ATP竞争性的,可逆的FAK抑制剂,IC50为1.5 nM,作用于Pyk2比作用于FAK选择性低10倍左右,比作用于其他蛋白激酶(除了一些CDKs)选择性高100倍以上。

    More
  • PF-562271 EY0368

    PF-562271, which is a potent ATP-competitive Pyk2/FAK dual inhibitor, has completed phase I clinical trial and is considered to be a promising drug for patients with solid tumors. PF-562271是一种有效的,ATP竞争性的,可逆的FAK抑制剂,IC50为1.5 nM,作用于Pyk2比作用于FAK选择性低10倍左右,比作用于其他蛋白激酶(除了一些CDKs)选择性高100倍以上。

    More
  • Current page1, Total Pages1, Total Record1 First Prev 1 Next Last Goto